Patents by Inventor Harry G. Brittain

Harry G. Brittain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230201147
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230201152
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 29, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • COMPOSITIONS COMPRISING COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE WITH TROMETHAMINE AND METHODS OF USE
    Publication number: 20230149427
    Abstract: Compositions comprising cocrystals of acetylsalicylic acid and theanine that have been formulated with tromethamine are provided. Methods of preparing the compositions and methods of using the compositions with optional zinc or dipyridamole treatments are also provided.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 18, 2023
    Inventors: Philip V. FELICE, Harry G. BRITTAIN, Paul WABNITZ
  • COCRYSTAL ANTIOXIDANTS OF PROTOCATECHUIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY CONDITIONS
    Publication number: 20230111210
    Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: October 28, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE, AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20230110872
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE ,AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20230115710
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 13, 2023
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20210177758
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • AMORPHOUS ONAPRISTONE COMPOSITIONS AND METHODS OF MAKING THE SAME
    Publication number: 20200376004
    Abstract: Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Application
    Filed: December 19, 2019
    Publication date: December 3, 2020
    Inventors: Harry G. Brittain, Stefan Proniuk
  • SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE, AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION
    Publication number: 20200101010
    Abstract: A water-soluble aspirin, citric acid, sodium bicarbonate, L-theanine cocrystal composition which includes a quantity of acetylsalicylic acid is described. The composition may be created by a method including various steps, including a cocrystallization step. The water-soluble cocrystal composition is suitable for sublingual administration, preferably to humans.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 2, 2020
    Applicant: THEAPRIN PHARMACEUTICALS, INC.
    Inventors: Philip V. FELICE, Harry G. BRITTAIN
  • Amorphous onapristone compositions and methods of making the same
    Patent number: 10548905
    Abstract: Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: February 4, 2020
    Assignee: CONTEXT BIOPHARMA INC.
    Inventors: Harry G. Brittain, Stefan Proniuk
  • Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
    Patent number: 10376464
    Abstract: Cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 13, 2019
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 10328070
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 25, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20190167664
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: November 27, 2018
    Publication date: June 6, 2019
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 10166228
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: January 1, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • POLYMORPHIC FORMS OF NALTREXONE
    Publication number: 20180303825
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 9980958
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 29, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20180110773
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 26, 2018
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • PLATFORM DRUG DELIVERY SYSTEM UTILIZING CRYSTAL ENGINEERING AND THEANINE DISSOLUTION
    Publication number: 20180064649
    Abstract: A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
    Type: Application
    Filed: February 29, 2016
    Publication date: March 8, 2018
    Applicant: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. BRITTAIN, Philip V. FELICE
  • Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
    Patent number: 9896411
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Polymorphic forms of naltrexone
    Patent number: 9827240
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 28, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright